Supporters

Diamond Supporters

BioCryst is a late-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives.

At BioCryst, we are passionate about advancing novel therapeutics for patients with rare and serious diseases.

BioCryst has its headquarters in Durham, North Carolina and its Discovery Center of Excellence in Birmingham, Alabama. With expertise in drug discovery, clinical development, and regulatory affairs, we are advancing clinical programs and generating new compounds from our own discovery engine.

We are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives.

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 240 years of distinguished history in Japan.

Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.

Gold Supporters

Silver Supporters

Established in 1997, BioMarin is a world leader in developing and commercializing first- or best-in-class therapies for rare genetic diseases. We take pride in going where the science leads us, pioneering breakthrough treatments for debilitating and life-threatening conditions where we can significantly improve upon the current standard of care.

Our culture revolves around the ethos that no disease should go untreated, and our people are driven to discover, develop, and commercialize medicines that give patients, their families, and their caregivers hope where there was little or none. We fuel our R&D engine by looking for opportunities that align with our strengths and competencies. And we relentlessly pursue exciting, early-stage science that has the potential to change the course of disease.

Intellia’s researchers work tirelessly to harness CRISPR-based genome editing also called gene editing. Genome editing collectively refers to a set of technologies, including CRISPR/Cas9, that can be used to cut and modify DNA. Genome editing uses systems to make the DNA change inside the cell. These cells can be edited in the body (in vivo) or outside the body (ex vivo) from a patient or donor. Technologies for human therapeutic use. In fact, one of Intellia’s co-founders, Jennifer Doudna, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. At Intellia, we are humbled to have a hand in making what we believe to be medical history. As a leader in this space, our responsibility and commitment to patients is critical in our pursuit of developing novel, potentially curative therapeutics utilizing CRISPR-based technologies.

Our passion for patients in need fuels our dedication to fill the therapeutic void with hope for the future. With RNA as the basis of our discovery platform, we are able to bring therapeutic options to patients who otherwise would have none.

Our antisense therapies are designed to interact precisely with RNA, allowing us to create treatments that disrupt the disease process and change its course. With three approved best- and first-in-class medicines and 10+ in mid- or late-stage development, our therapeutic breakthroughs are poised to continue to transform the futures of patients for years to come.

Our work with patients and families inspires us, and our commitment to serving them is what fuels us to truly make a positive difference in their lives. With patient needs as our central focus, we have become the leader in the discovery and development of antisense therapies; RNA-based therapies that allow us to target disease at the source, from the rarest of diseases, to those that impact millions of people.

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need. Our initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. We have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). As part of the strategy, we will select molecules whose properties can support multiple therapies for HAE patients, such as for prophylactic as well as acute treatment.

Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE safe, effective, and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.